Impact of perineural invasion on the outcome of patients with synchronous colorectal liver metastases treated with neoadjuvant chemotherapy and surgery.


Journal

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
ISSN: 1699-3055
Titre abrégé: Clin Transl Oncol
Pays: Italy
ID NLM: 101247119

Informations de publication

Date de publication:
Aug 2023
Historique:
received: 10 10 2022
accepted: 26 02 2023
medline: 28 6 2023
pubmed: 8 4 2023
entrez: 7 4 2023
Statut: ppublish

Résumé

To analyze the prognostic value of variables of the primary tumor in patients with synchronous liver metastases in colorectal cancer (CLRMs) treated with neoadjuvant chemotherapy and surgery. From a prospective database, we retrospectively identified all patients with synchronous CLRMs who were treated with neoadjuvant chemotherapy and liver resection. Using univariate and multivariate analyses, we identified the variables associated with tumor recurrence. Overall survival and disease-free survival were calculated using the Kaplan-Meier method with differences determined by the Cox multiple hazards model. Results were compared using the log-rank test. Ninety-eight patients with synchronous CLRMs were identified. With a median follow-up of 39.8 months, overall survival and disease-free survival at 5 and 10 years were 53%, 41.7%, 29% and 29%, respectively. Univariate analysis identified three variables associated with tumor recurrence: location in the colon (p = 0.025), lymphovascular invasion (p = 0.011) and perineural invasion (p = 0.005). Multivariate analysis identified two variables associated with worse overall survival: perineural invasion (HR 2.36, 95% CI 1.162-4.818, p = 0.018) and performing frontline colectomy (HR 3.286, 95% CI 1.256-8.597, p = 0.015). Perineural invasion remained as the only variable associated with lower disease-free survival (HR 1.867, 95% CI 1.013-3.441, p = 0.045). Overall survival at 5 and 10 years in patients with and without perineural invasion was 68.2%, 54.4% and 29.9% and 21.3%, respectively (HR 5.920, 95% CI 2.241-15.630, p < 0.001). Perineural invasion in the primary tumor is the variable with most impact on survival in patients with synchronous CLRMs treated with neoadjuvant chemotherapy and surgery.

Identifiants

pubmed: 37027061
doi: 10.1007/s12094-023-03138-0
pii: 10.1007/s12094-023-03138-0
pmc: PMC10293410
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2523-2531

Informations de copyright

© 2023. The Author(s).

Références

Ann Surg Oncol. 2017 Apr;24(4):1077-1084
pubmed: 27624582
J Natl Compr Canc Netw. 2018 Jul;16(7):874-901
pubmed: 30006429
Cancer Treat Rev. 2015 Nov;41(9):729-41
pubmed: 26417845
J Clin Oncol. 2009 Nov 1;27(31):5131-7
pubmed: 19738119
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Ann Surg. 1999 Sep;230(3):309-18; discussion 318-21
pubmed: 10493478
Cancer. 2012 Feb 1;118(3):628-38
pubmed: 21751188
Am J Surg Pathol. 2016 Jan;40(1):103-12
pubmed: 26426380
Ann Surg. 2014 Nov;260(5):900-7; discussion 907-8
pubmed: 25379860
Ann Surg. 2006 Aug;244(2):254-9
pubmed: 16858188
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
JMA J. 2020 Jul 15;3(3):240-250
pubmed: 33150258
Ann Otol Rhinol Laryngol. 1985 Jul-Aug;94(4 Pt 1):426-7
pubmed: 4026129
Clin Transl Oncol. 2019 Jan;21(1):46-54
pubmed: 30565083
Arch Pathol Lab Med. 2009 Oct;133(10):1539-51
pubmed: 19792043
HPB (Oxford). 2010 May;12(4):227-38
pubmed: 20590892
Nat Rev Cancer. 2020 Mar;20(3):143-157
pubmed: 31974491
J Natl Compr Canc Netw. 2018 Apr;16(4):359-369
pubmed: 29632055
Ann Surg Oncol. 2006 Oct;13(10):1261-8
pubmed: 16947009
Ann Surg Oncol. 2013 Jan;20(1):148-54
pubmed: 22847127
Ann Surg Oncol. 2015 Mar;22(3):916-23
pubmed: 25190129
Ann Surg. 2000 Jan;231(1):59-66
pubmed: 10636103
Cancer. 2011 Nov 1;117(21):4834-45
pubmed: 21480205
Clin Cancer Res. 2013 Jan 1;19(1):50-61
pubmed: 23147996
J Natl Compr Canc Netw. 2013 Feb 1;11(2):141-52; quiz 152
pubmed: 23411381

Auteurs

Gabriel Zozaya (G)

Department of General Surgery, School of Medicine, Clínica Universidad de Navarra, University of Navarra, Av. Pío XII, 36, 31008, Pamplona, Spain. gnzozaya@unav.es.

Javier Álvarez Cienfuegos (JÁ)

Department of General Surgery, School of Medicine, Clínica Universidad de Navarra, University of Navarra, Av. Pío XII, 36, 31008, Pamplona, Spain.
Institute of Health Research of Navarra (IdisNA), Pamplona, Spain.
CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III, 31008, Pamplona, Spain.

Pablo Martí-Cruchaga (P)

Department of General Surgery, School of Medicine, Clínica Universidad de Navarra, University of Navarra, Av. Pío XII, 36, 31008, Pamplona, Spain.

José Luis Hernández-Lizoain (JL)

Department of General Surgery, School of Medicine, Clínica Universidad de Navarra, University of Navarra, Av. Pío XII, 36, 31008, Pamplona, Spain.
Institute of Health Research of Navarra (IdisNA), Pamplona, Spain.

Jorge Baixauli (J)

Department of General Surgery, School of Medicine, Clínica Universidad de Navarra, University of Navarra, Av. Pío XII, 36, 31008, Pamplona, Spain.

Fernando Pardo (F)

Department of General Surgery, School of Medicine, Clínica Universidad de Navarra, University of Navarra, Av. Pío XII, 36, 31008, Pamplona, Spain.

Ramón Robledano (R)

Department of Pathology, School of Medicine, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain.

Javier Rodríguez (J)

Department of Medical Oncology, School of Medicine, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain.

Leire Arbea (L)

Department of Radiation Oncology, School of Medicine, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain.

Fernando Rotellar (F)

Department of General Surgery, School of Medicine, Clínica Universidad de Navarra, University of Navarra, Av. Pío XII, 36, 31008, Pamplona, Spain.
Institute of Health Research of Navarra (IdisNA), Pamplona, Spain.
CIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Instituto de Salud Carlos III, 31008, Pamplona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH